GlaxoSmithKline plc GSK – Update
We attempted to keep our excellent 2019 options performance intact yesterday, and we did see some chances for intraday gains in the fresh idea for GSK we included in our premarket report.
The stock didn’t skyrocket by any means, rising by less than a dollar, but the activity was sufficient to produce the following moves in our designated contracts.
$39.50 Calls – Range: .65-1.24 – Max Gain: 91%
$40 Calls – Range: .15-.75 – Max Gain: 400%
$40.50 Calls – Range: .10-.40 – Max Gain: 300%
GRUB Weekly $86-87.50 Calls
Calix, Inc. CALX &
Vanda Pharmaceuticals, Inc. VNDA
We want to group these two stocks together this morning and tag them as bottom-watch plays. We’ll observe for the establishment of higher lows after their recent selloffs.
Both are now in the position of being extremely oversold, and exhibiting many of the conditions we routinely look for in potential recovery plays. We’ll observe their activity as we head into the end of the week.
DRVD, PYDS, NVCN, TPNL, BIOC